Literature DB >> 32016103

Immunotherapy combinations transform the treatment paradigm for advanced renal cell carcinoma.

Justin A Shaya1, Rana R McKay1.   

Abstract

Entities:  

Year:  2019        PMID： 32016103      PMCID： PMC6976508          DOI： 10.21037/atm.2019.12.130

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  12 in total

1.  Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

Authors:  Toni K Choueiri; Susan Halabi; Ben L Sanford; Olwen Hahn; M Dror Michaelson; Meghara K Walsh; Darren R Feldman; Thomas Olencki; Joel Picus; Eric J Small; Shaker Dakhil; Daniel J George; Michael J Morris
Journal:  J Clin Oncol       Date:  2016-11-14       Impact factor: 44.544

2.  Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

Authors:  Robert J Motzer; Brian I Rini; David F McDermott; Osvaldo Arén Frontera; Hans J Hammers; Michael A Carducci; Pamela Salman; Bernard Escudier; Benoit Beuselinck; Asim Amin; Camillo Porta; Saby George; Victoria Neiman; Sergio Bracarda; Scott S Tykodi; Philippe Barthélémy; Raya Leibowitz-Amit; Elizabeth R Plimack; Sjoukje F Oosting; Bruce Redman; Bohuslav Melichar; Thomas Powles; Paul Nathan; Stéphane Oudard; David Pook; Toni K Choueiri; Frede Donskov; Marc-Oliver Grimm; Howard Gurney; Daniel Y C Heng; Christian K Kollmannsberger; Michael R Harrison; Yoshihiko Tomita; Ignacio Duran; Viktor Grünwald; M Brent McHenry; Sabeen Mekan; Nizar M Tannir
Journal:  Lancet Oncol       Date:  2019-08-16       Impact factor: 41.316

3.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Authors:  Brian I Rini; Elizabeth R Plimack; Viktor Stus; Rustem Gafanov; Robert Hawkins; Dmitry Nosov; Frédéric Pouliot; Boris Alekseev; Denis Soulières; Bohuslav Melichar; Ihor Vynnychenko; Anna Kryzhanivska; Igor Bondarenko; Sergio J Azevedo; Delphine Borchiellini; Cezary Szczylik; Maurice Markus; Raymond S McDermott; Jens Bedke; Sophie Tartas; Yen-Hwa Chang; Satoshi Tamada; Qiong Shou; Rodolfo F Perini; Mei Chen; Michael B Atkins; Thomas Powles
Journal:  N Engl J Med       Date:  2019-02-16       Impact factor: 91.245

4.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

Review 5.  Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies.

Authors:  Brian Shuch; Gennady Bratslavsky; W Marston Linehan; Ramaprasad Srinivasan
Journal:  Oncologist       Date:  2012-01-10

6.  Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Konstantin Penkov; John Haanen; Brian Rini; Laurence Albiges; Matthew T Campbell; Balaji Venugopal; Christian Kollmannsberger; Sylvie Negrier; Motohide Uemura; Jae L Lee; Aleksandr Vasiliev; Wilson H Miller; Howard Gurney; Manuela Schmidinger; James Larkin; Michael B Atkins; Jens Bedke; Boris Alekseev; Jing Wang; Mariangela Mariani; Paul B Robbins; Aleksander Chudnovsky; Camilla Fowst; Subramanian Hariharan; Bo Huang; Alessandra di Pietro; Toni K Choueiri
Journal:  N Engl J Med       Date:  2019-02-16       Impact factor: 91.245

Review 7.  Pitfalls in the radiological response assessment of immunotherapy.

Authors:  Lucian Beer; Maximilian Hochmair; Helmut Prosch
Journal:  Memo       Date:  2018-03-21

Review 8.  Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data.

Authors:  Patrick A Ott; F Stephen Hodi; Elizabeth I Buchbinder
Journal:  Front Oncol       Date:  2015-09-22       Impact factor: 6.244

9.  Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.

Authors:  Toni K Choueiri; Colin Hessel; Susan Halabi; Ben Sanford; M Dror Michaelson; Olwen Hahn; Meghara Walsh; Thomas Olencki; Joel Picus; Eric J Small; Shaker Dakhil; Darren R Feldman; Milan Mangeshkar; Christian Scheffold; Daniel George; Michael J Morris
Journal:  Eur J Cancer       Date:  2018-03-20       Impact factor: 9.162

10.  Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma.

Authors:  Meredith M Regan; Lillian Werner; Sumati Rao; Komal Gupte-Singh; F Stephen Hodi; John M Kirkwood; Harriet M Kluger; James Larkin; Michael A Postow; Corey Ritchings; Mario Sznol; Ahmad A Tarhini; Jedd D Wolchok; Michael B Atkins; David F McDermott
Journal:  J Clin Oncol       Date:  2019-09-09       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.